Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present PharmaCyte Biotech, Inc. (OTC: PMCB).

Full DD Report for PMCB

You must become a subscriber to view this report.


Recent News from (OTC: PMCB)

Pot stocks perk up premarket
Cannabis stocks are showing some life premarket. Cronos Group (NASDAQ: CRON ) is up  24%  on robust volume, Canopy Growth (NYSE: CGC ) is up  7%  on increased volume and Tilray (NASDAQ: TLRY ) is up  11%  on average volume. More news on: Cronos Group, Inc., Ca...
Source: SeekingAlpha
Date: September, 05 2018 07:50
Citron bearish on Tilray due to valuation; shares up 9%
Citron Research, a buyer of pot stock Tilray ( TLRY +9.4% ) up to $45, is now bearish with a fair value target of $26, calling it "by far the most expensive in the space." The stock is currently exchanging hands at $72 up over four-fold from its IPO price of $17. More news on: Tilray, In...
Source: SeekingAlpha
Date: September, 04 2018 12:19
Profit-taking pressures Tilray, down 4% premarket
Tilray (NASDAQ: TLRY ) slips  4%  premarket on light volume as investors take money off the table after the stock's ~ 160%  run-up since touching $24 on August 14. More news on: Tilray, Inc., Canopy Growth Corporation, Cronos Group, Inc., Healthcare stocks news, Consumer sto...
Source: SeekingAlpha
Date: August, 30 2018 08:09
Trump's secret war on weed - BuzzFeed
The administration's Marijuana Policy Coordination Committee is aiming to combat public support for marijuana and throw a negative spin on state legalization initiatives, writes Dominic Holden. More news on: Tilray, Inc., Canopy Growth Corporation, Cronos Group, Inc., Healthcare stock...
Source: SeekingAlpha
Date: August, 29 2018 13:51
Beverage giants eye Canadian cannabis players
The large investment by Constellation Brands ( STZ +1.1% ) in Canopy Growth Corp. ( CGC +3.8% ) is still reverberating around the beverage industry as some of the larger names scramble to keep up. More news on: Constellation Brands, Inc., Canopy Growth Corporation, Anheuser-Busch InB...
Source: SeekingAlpha
Date: August, 29 2018 10:42
Diageo eyeing cannabis-infused beverages
Bloomberg reports that top alcohol producer Diageo Plc (NYSE: DEO ), aiming to boost growth and fend off competitors, is in discussions with at least three major Canadian producers to add cannabis-infused beverages to its portfolio. More news on: Diageo plc, Molson Coors Brewing Company,...
Source: SeekingAlpha
Date: August, 24 2018 07:26
U.S. pot market could be worth $47B - RBC #2
In a note , RBC Capital Markets says that legal sales of marijuana in the U.S. are catching up to beer and wine, potentially reaching $47B in ten years, implying a 17% CAGR. More news on: MJ Holdings, Inc., MyDx, Inc., Mountain High Acquisitions Corp., Healthcare stocks news, Consumer sto...
Source: SeekingAlpha
Date: August, 22 2018 09:55
Weed firms set for bullish action ahead of start of Canada recreational pot market
Cannabis-related stocks may see broad buying today as they announce supply agreements with retail operations ahead of the launch of the adult-use recreational cannabis market in Canada on October 17. Cronos Group (NASDAQ: CRON ) and Tilray (NASDAQ: TLRY ) have already announced deals. Both a...
Source: SeekingAlpha
Date: August, 21 2018 08:07
Tilray up 20% on Citron touch
"Today is the day that everything has changed in Cannabis," tweets Andrew Left . "Real $$$ into space. Next to get support should be Tilray ( TLRY +19.8% )." More news on: Tilray, Inc., Horizons Marijuana Life Sciences Index ETF, Cannimed Therapeutics Inc., Consumer stocks news, Healthc...
Source: SeekingAlpha
Date: August, 15 2018 12:59
Significant portion of California pot failing safety tests
Cannabis consumers in California should be aware that they may be ingesting weed that lags state-sanctioned safety standards that went into effect July 1. More news on: Horizons Marijuana Life Sciences Index ETF, Cannimed Therapeutics Inc., Medical Marijuana, Inc., Healthcare stocks news, ...
Source: SeekingAlpha
Date: July, 31 2018 12:27

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-190.04380.04060.04380.0405206,288
2018-12-180.043250.0420.04490.0415869,437
2018-12-170.045550.04350.04760.0401886,630
2018-12-140.044050.04350.04590.041,902,172
2018-12-130.04670.04450.04760.044495927,578

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-18295,361869,43733.9715Cover
2018-12-17467,436886,63052.7205Short
2018-12-14969,2941,902,17250.9572Short
2018-12-13468,123927,57850.4672Short
2018-12-12538,2131,520,73535.3916Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PMCB.


About PharmaCyte Biotech, Inc. (OTC: PMCB)

Logo for PharmaCyte Biotech, Inc. (OTC: PMCB)

PharmaCyte is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose based live cell encapsulation technology known as Cell in a Box. This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. For cancer, the therapy involves encapsulating genetically engineered human cells that convert the prodrug ifosfamide from its inactive form to its cancer killing form. These encapsulated live cells are implanted in a patient as close to the tumor as possible. Then ifosfamide is given IV at one third the normal dose. When the ifosfamide comes in contact with the encapsulated live cells, they act as an artificial liver where ifosfamide is normally activated and activate the ifosfamide at the source of the cancer. For diabetes, PharmaCyte is developing a treatment for Type diabetes and insulin dependent Type diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is also exploring the use of beta islet cells to treat Type and insulin dependent Type diabetes. The encapsulation of these cells will be done using the Cell in a Box technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a bio artificial pancreas for purposes of insulin production.

 

 

 

Current Management

  • Kenneth L. Waggoner, JD / CEO, President, General Counsel
    • Kenneth L. Waggoner commenced employment with PharmaCyte in September . He became the Chief Executive Officer and President in November . Shortly thereafter, Mr. Waggoner assumed the additional position of General Counsel. Mr. Waggoner serves as Chairman of the Board. Mr. Waggoner has over four decades of experience in management, business, operations and the practice of law. Mr. Waggoner began his professional career as an attorney in private practice in with the law firm of Lawler, Felix amp Hall. From to , he was a senior partner with Brobeck, Phleger and Harrison, where he was the Managing Partner of Brobeck s Los Angeles office. Brobeck provided services to biotechnology clients such as Chiron, Amgen, Biogen Idec, Sangamo, Ligand, DepoTech and many others. While at Brobeck, Mr. Waggoner served as a member of the Executive Committee for almost ten years and on the Policy Committee for numerous years managing Brobeck s worldwide operations with annual revenues in excess of , , . Mr. Waggoner was the coChairman of Brobeck s worldwide Environmental Law Group. Mr. Waggoner s career included leadership and legal positions with Fortune companies most of his professional career. From to , Mr. Waggoner served as the Vice President and General Counsel of Chevron s global downstream operations where he was responsible for the overall management of legal services to the North American, Latin American, Europe and Asian Products Companies.
  • Gerald W. Crabtree, PhD / COO
    • Gerald W. Crabtree, Ph.D. is the Chief Operating Officer of PharmaCyte. He also services as a Director. Dr. Crabtree has over years of experience in the biomedical sciences sector, having been involved with various pharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates. prepared clinical protocols, Dr. Crabtree served as the Director of Project Planning and Management Oncology and Immunology at BristolMyers Squibb from to . While at BMS, Dr. Crabtree established and directed a department that monitored and coordinated the development of all oncologic and immunologic drugs from initial discovery through regulatory approval. He also served as Project Manager for the development of the major anticancer agent, Taxol, the number one drug under development at BMS at that time. Taxol ultimately became a multibillion dollar drug for BMS and is still widely used to treat a variety of cancers. From to , Dr. Crabtree was Director of Pharmacology at Viratek, Inc., a subsidiary of ICN Pharmaceuticals, Inc. in Costa Mesa, California, where he worked on the development of anticancer drugs first developed at the Nucleic Acid Research Institute, a joint venture between Eastman Kodak and ICN Pharmaceuticals. He also coordinated the development of ribavirin Virazole , Viratek s landmark antiviral drug.
  • Carlos A. Trujillo / CFO
    • Carlos A. Trujillo serves as the Chief Financial Officer of PharmaCyte Biotech and is a member of PharmaCyte s Board of Directors. Mr. Trujillo is a Certified Public Accountant licensed by the State of California. He has years of experience in finance, accounting and management. Mr. Trujillo started his career in public accounting and was the manager of an audit department. Mr. Trujillo then established a consulting and accounting practice which he operated for ten years and provided services as the Chief Financial Accountant to numerous organizations in several different industries. His experience has extended to companies in the biotechnology, telecommunications, manufacturing, construction and real estate development sectors. Mr. Trujillo has been the Chief Financial Officer for both privatelyheld and publiclytraded, multinational companies. He brings extensive experience to PharmaCyte in preparing and filing periodic reports with the Securities and Exchange Commission, in mergers and acquisitions and in the filing of comprehensive financial statements and reports. Mr. Trujillo received his Bachelor s Degree in Accounting in from California State University, Fullerton.
  • Kenneth L. Waggoner, JD / Chairman
    • Kenneth L. Waggoner commenced employment with PharmaCyte in September . He became the Chief Executive Officer and President in November . Shortly thereafter, Mr. Waggoner assumed the additional position of General Counsel. Mr. Waggoner serves as Chairman of the Board. Mr. Waggoner has over four decades of experience in management, business, operations and the practice of law. Mr. Waggoner began his professional career as an attorney in private practice in with the law firm of Lawler, Felix amp Hall. From to , he was a senior partner with Brobeck, Phleger and Harrison, where he was the Managing Partner of Brobeck s Los Angeles office. Brobeck provided services to biotechnology clients such as Chiron, Amgen, Biogen Idec, Sangamo, Ligand, DepoTech and many others. While at Brobeck, Mr. Waggoner served as a member of the Executive Committee for almost ten years and on the Policy Committee for numerous years managing Brobeck s worldwide operations with annual revenues in excess of , , . Mr. Waggoner was the coChairman of Brobeck s worldwide Environmental Law Group. Mr. Waggoner s career included leadership and legal positions with Fortune companies most of his professional career. From to , Mr. Waggoner served as the Vice President and General Counsel of Chevron s global downstream operations where he was responsible for the overall management of legal services to the North American, Latin American, Europe and Asian Products Companies.
  • Thomas Liquard / Independent Director, Audit Committee Member, Compensation Committee Member
    • Thomas Liquard was appointed to the Board in April . Mr. Liquard has more than a decade of experience in the pharmaceutical industry, having held various commercialization, product development and leadership roles with large pharmaceutical and biotechnology companies. He is currently the CEO of Immuron, a Melbournebased pharmaceutical company. Prior to Immuron, Mr. Liquard served as the CEO and COO of Alchemia, a major Australian pharmaceutical company. Mr. Liquard spent seven years with Pfizer, Inc. based in New York, where he held various senior commercial positions. His last was as Senior Director, Portfolio Development Leader and Emerging Markets for the Established Products portfolio. In that role, Mr. Liquard drove business development M amp A, licensing, partnerships and internal product development initiatives.
  • Michael M. Abecassis, MD / Independent Director, Nominating Committee Member
    • Dr. Abecassis is the Director of the Comprehensive Transplant Center of the Feinberg School of Medicine. He is also the Chief of Transplant Surgery in the Department of Surgery at Feinberg and a James Roscoe Miller Distinguished Professor of Medicine at Feinberg. Dr. Abecassis received his Medical Degree from the University of Toronto in and was awarded a Master of Business Administration degree from the Kellogg School of Management at Northwestern University in . After his postgraduate tenure in Toronto, Dr. Abecassis began his clinical career as Assistant Professor of Surgery and Director of Liver Transplantation and Hepatobiliary Surgery at the University of Iowa. In , Dr. Abecassis became Northwestern University s Director of Liver Transplantation, where he initiated Northwestern s liver transplant program. In , Dr. Abecassis was named Chief of the Division of Transplantation at the Feinberg School of Medicine. He became Founding Director of the Comprehensive Transplant Center at Northwestern in and was appointed Dean for Clinical Affairs at the Feinberg School of Medicine in , serving until .
  • Gerald W. Crabtree, PhD / Compensation Committee Member
    • Gerald W. Crabtree, Ph.D. is the Chief Operating Officer of PharmaCyte. He also services as a Director. Dr. Crabtree has over years of experience in the biomedical sciences sector, having been involved with various pharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates. prepared clinical protocols, Dr. Crabtree served as the Director of Project Planning and Management Oncology and Immunology at BristolMyers Squibb from to . While at BMS, Dr. Crabtree established and directed a department that monitored and coordinated the development of all oncologic and immunologic drugs from initial discovery through regulatory approval. He also served as Project Manager for the development of the major anticancer agent, Taxol, the number one drug under development at BMS at that time. Taxol ultimately became a multibillion dollar drug for BMS and is still widely used to treat a variety of cancers. From to , Dr. Crabtree was Director of Pharmacology at Viratek, Inc., a subsidiary of ICN Pharmaceuticals, Inc. in Costa Mesa, California, where he worked on the development of anticancer drugs first developed at the Nucleic Acid Research Institute, a joint venture between Eastman Kodak and ICN Pharmaceuticals. He also coordinated the development of ribavirin Virazole , Viratek s landmark antiviral drug.
  • Raymond C.F. Tong / Audit Committee Member
    • Dr. Tong serves as Chief Executive Officer of Harmony Medical Inc., an Asian investment group active in the introduction and distribution of medical and healthcare products and services in China and throughout Asia. He is also Chairman of the Business Development Committee of Shanghai Kedu Healthcare Group, the largest medical equipment thirdparty service provider in China, representing products from GE, Philips, Siemens, Kodak and other multinationals as well as local companies. Dr. Tong is the founding Director and Chief Executive Officer of VetCell Therapeutics Asia, a cell therapy company focused on providing cellbased treatments for use in veterinary medicine in Asia. Dr. Tong received his medical degree from the University of Toronto in Ontario, Canada in . He also received a Ph.D. degree in neurophysiology and an M.B.A. degree.
  • Carlos A. Trujillo / Director
    • Carlos A. Trujillo serves as the Chief Financial Officer of PharmaCyte Biotech and is a member of PharmaCyte s Board of Directors. Mr. Trujillo is a Certified Public Accountant licensed by the State of California. He has years of experience in finance, accounting and management. Mr. Trujillo started his career in public accounting and was the manager of an audit department. Mr. Trujillo then established a consulting and accounting practice which he operated for ten years and provided services as the Chief Financial Accountant to numerous organizations in several different industries. His experience has extended to companies in the biotechnology, telecommunications, manufacturing, construction and real estate development sectors. Mr. Trujillo has been the Chief Financial Officer for both privatelyheld and publiclytraded, multinational companies. He brings extensive experience to PharmaCyte in preparing and filing periodic reports with the Securities and Exchange Commission, in mergers and acquisitions and in the filing of comprehensive financial statements and reports. Mr. Trujillo received his Bachelor s Degree in Accounting in from California State University, Fullerton.
  • Thomas C.K. Yuen / Independent Director, Compensation Committee Member
    • Thomas C. K. Yuen was appointed to the Board in May . Mr. Yuen has more than three decades of experience in entrepreneurship and business leadership, including in the biotech industry. Mr. Yuen cofounded Irvinebased AST Research, Inc. AST in . AST was an early pioneer of the computer industry, and the company has been referred to as the flagship of innovation in the PC era. Mr. Yuen served as AST s CoChairman and Chief Operating Officer from August to June . Mr. Yuen left AST in and focused his efforts on investing in new projects. Mr. Yuen served in various engineering and project management positions with Hughes Aircraft Company, Sperry Univac and Computer Automation. Later in his career, Mr. Yuen became Chairman and CEO of SRS Labs, a world leader in audio and voice technology. Currently, Mr. Yuen is Chairman and Chief Executive Officer of PrimeGen Biotech, a private cell therapy company he founded in .

Current Share Structure

  • Market Cap: $50,680,057 - 03/15/2018
  • Authorized: 1,490,000,000 - 03/08/2018
  • Issue and Outstanding: 1,013,601,144 - 03/08/2018
  • Float: 968,101,144 - 03/08/2018

 


Recent Filings from (OTC: PMCB)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: March, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 22 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: February, 22 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: December, 14 2017
Correspondence from the SEC to the Filer
Filing Type: UPLOADFiling Source: edgar
Filing Date: November, 06 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: October, 10 2017
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: September, 28 2017
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: September, 28 2017
OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: September, 27 2017

 

 


Daily Technical Chart for (OTC: PMCB)

Daily Technical Chart for (OTC: PMCB)


Stay tuned for daily updates and more on (OTC: PMCB)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: PMCB)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PMCB is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of PMCB and does not buy, sell, or trade any shares of PMCB. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/